The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Prospective clinical pilot study for subjects diagnosed with Occupational Progressive
Pneumoconiosis.
Subjects will be treated with Nintedanib 150mg twice daily for 3 years.